Nasdaq-listed cancer diagnostics specialist NeoGenomics has acquired a majority stake in Cambridge-based Inivata – a cancer genomics company backed by a pool of VC investors – for $390m.
Buyout reportedly values the pharmaceutical glass packaging producer at around €900m
Vehicle will co-invest in European tech scale-ups alongside the venture capital funds in which it is invested
Procuritas will become the majority shareholder, while the founders of the companies will have a significant minority ownership of the merged entity
ProFounders Capital scores 25x money on the listing; other investors include Partech